Radioimmunoguided treatment of cancer

By | October 28, 2011

Radioimmunoguided tumor therapy: is the use of radionuclide labeled monoclonal antibody to achieve local tumor irradiation therapy, with a significant effect, the advantages of low adverse reactions. The most common is to use I labeled monoclonal antibody treatment of refractory or relapsed B-cell lymphoma, esophageal and gastrointestinal cancer, liver cancer. To intravenous injection, local administration can also be cancer.
Radioimmunoguided tumor therapy (1) 131I-rituximab in the treatment of refractory or relapsed B-cell lymphoma: rituximab 100 mg marked 1591_2664MBq (43_72mCi) 131I, 1 / 3 for intratumoral injection, 2 / 3 as intravenous drip 3 months into the 2-repeat 1.
Radioimmunoguided tumor therapy (2) 31I-MIBG treatment of adrenal tumors Ming: 131I-MIBG 3700_5550MBq (100-150mCi) dissolved in 500 ml of normal saline, intravenous infusion 2 hours, 3-6 months 1 injection.
Radioimmunoguided tumor therapy (3) 131I labeled monoclonal antibody mixture (CL-3, T-9) for gastrointestinal cancer: 9 mg of monoclonal antibody labeled mixed 131I1924-2590MBq (52-70mCi), intratumoral injection.
Radioimmunoguided tumor therapy (4) mixed labeled monoclonal antibody 1311 (S-102, T-9, CL-3) treatment of primary liver cancer : 14 mg of mixed monoclonal antibody labeled 131I2035-2812MBq (55-76mCi), intratumoral injection. 1 week before treatment 2 weeks after administration of 2% shy of taking the bait solution, each 20 ml, 3 times a day to protect the thyroid gland.

Leave a Reply

Your email address will not be published. Required fields are marked *